Sarclisa Is Likely to Be Managed At Parity With Similar Drugs
On March 2, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) for the treatment of multiple myeloma, a hematologic malignancy. The move added another therapy to a class full of products, both indicated for the condition and used off label. Almost half of payers responding to a Zitter Insights survey said they anticipate their company will manage the new treatment on parity with other multiple myeloma drugs that have a similar indication.
The FDA approved Sarclisa, a CD39-directed cytolytic antibody, for use in combination with Pomalyst (pomalidomide) and dexamethasone (pom-dex or Pd) — the latter of which is available under multiple brand names — for the treatment of adults with relapsed refractory multiple myeloma who have received at least two therapies including Celgene Corp.’s Revlimid (lenalidomide) and a proteasome inhibitor (RSP 3/20, p. 8).
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Senior Editor, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile